We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$18.2B
AUM Growth
-$235M
Cap. Flow
-$283M
Cap. Flow %
-1.55%
Top 10 Hldgs %
32.02%
Holding
333
New
17
Increased
37
Reduced
36
Closed
22

Top Buys

Rank Stock Value
1
ZEN
ZENDESK INC
ZEN
+$262M
2
CLVT icon
Clarivate
CLVT
+$202M
3
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$196M
4
SPGI icon
S&P Global
SPGI
+$139M
5
HUM icon
Humana
HUM
+$122M

Top Sells

Rank Stock Value
1
COHR
Coherent Inc
COHR
+$154M
2
HWM icon
Howmet Aerospace
HWM
+$140M
3
CSGP icon
CoStar Group
CSGP
+$139M
4
BSX icon
Boston Scientific
BSX
+$116M
5
MANT
Mantech International Corp
MANT
+$92.7M

Sector Composition

Rank Sector Weight
1 Healthcare 28.39%
2 Technology 19.07%
3 Financials 13.73%
4 Industrials 8.28%
5 Communication Services 8.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
51
Sarepta Therapeutics
SRPT
$1.98B
$83.5M 0.46%
754,950
-430,101
-36% -$43.4M
BIIB icon
52
Biogen
BIIB
$32B
$81.6M 0.45%
305,499
+27,000
+10% +$5.73M
MASI
53
DELISTED
Masimo
MASI
$81.4M 0.45%
577,000
+382,000
+196% +$55.8M
ENTA icon
54
Enanta Pharmaceuticals
ENTA
$392M
$80.4M 0.44%
1,550,000
– –
PCG icon
55
PG&E
PCG
$38.8B
$78.8M 0.43%
6,305,142
– –
CYTK icon
56
Cytokinetics
CYTK
$10.7B
$78.5M 0.43%
1,621,038
-624,000
-28% -$30M
AVTR icon
57
Avantor
AVTR
$9.78B
$72.1M 0.4%
3,679,464
-1,600,000
-30% -$42.9M
JAZZ icon
58
Jazz Pharmaceuticals
JAZZ
$16.5B
$71.6M 0.39%
537,500
-382,600
-42% -$58.2M
NLSN
59
DELISTED
Nielsen Holdings plc
NLSN
$68.5M 0.38%
+2,470,976
New +$64.4M
SIMO icon
60
Silicon Motion
SIMO
$8.76B
$60.7M 0.33%
931,510
+155,000
+20% +$12.1M
LU icon
61
Lufax Holding
LU
$1.2B
$52.2M 0.29%
5,134,100
-801,000
-13% -$13.7M
ONEM
62
DELISTED
1Life Healthcare
ONEM
$50.2M 0.28%
+2,925,000
New +$45.9M
BRKR icon
63
Bruker
BRKR
$9.07B
$50.1M 0.28%
943,800
-463,000
-33% -$27.7M
RVMD icon
64
Revolution Medicines
RVMD
$44.9B
$49.3M 0.27%
2,500,000
-750,000
-23% -$16.5M
TSEM icon
65
Tower Semiconductor
TSEM
$25.2B
$44.6M 0.25%
1,015,000
+65,000
+7% +$2.99M
LH icon
66
Labcorp
LH
$27.3B
$44.1M 0.24%
250,625
-353,158
-58% -$72.3M
AGIO icon
67
Agios Pharmaceuticals
AGIO
$1.98B
$42.3M 0.23%
1,496,829
+163,817
+12% +$4.39M
CCXI
68
DELISTED
ChemoCentryx, Inc.
CCXI
$41.3M 0.23%
+800,000
New +$33.1M
IMGO
69
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$37.2M 0.2%
2,471,313
– –
BABA icon
70
Alibaba
BABA
$286B
$37.1M 0.2%
+464,000
New +$44.2M
CTLT
71
DELISTED
CATALENT, INC.
CTLT
$33.7M 0.19%
465,755
+46,000
+11% +$4.57M
APLS
72
DELISTED
Apellis Pharmaceuticals
APLS
$32.6M 0.18%
+478,000
New +$28.3M
FHN icon
73
First Horizon
FHN
$11.7B
$32.1M 0.18%
+1,400,000
New +$31.8M
IS
74
DELISTED
ironSource Ltd.
IS
$31.4M 0.17%
+9,130,000
New +$34.8M
PTGX icon
75
Protagonist Therapeutics
PTGX
$9.99B
$30.8M 0.17%
3,651,887
-48,721
-1% -$461K
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2022 Portfolio in Review

As of Q3 2022, Thomas Steyer held 333 positions worth $18.2B, down 1.3% from $18.4B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer's Q3 2022 filing shows 17 new, 37 increased, 36 reduced and 22 closed positions. Its largest new stake was Humana: 251,200 shares worth $122M. The largest sale was Coherent Inc, an estimated $154M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

  • Thomas Steyer's largest Q3 2022 buy was Humana: 251,200 shares worth $122M.
  • Thomas Steyer added most to ZENDESK INC in Q3 2022, an estimated $262M increase.
  • Thomas Steyer's biggest Q3 2022 reduction was Howmet Aerospace, cutting an estimated $140M.
  • Thomas Steyer fully exited Coherent Inc in Q3 2022, selling an estimated $154M.
  • Thomas Steyer's ten largest holdings make up 32% of its $18.2B portfolio in Q3 2022.
  • Thomas Steyer opened 17 new positions and closed 22 in Q3 2022.
  • Thomas Steyer's portfolio value fell 1.3% quarter-over-quarter to $18.2B.

Based on Farallon Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.